5-FU (5-fluorouracil)

DRUG2 trials

Sponsors

Gruppo Oncologico del Nord-Ovest, Akeso

Conditions

Advanced Solid TumorsColorectal AdenocarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer Stage IIIB/IVPancreatic Adenocarcinoma Advanced or Metastatic

Phase 1

AK129 Combination Therapy for Advanced Solid Tumors

RecruitingNCT06943820

AkesoAdvanced Solid Tumors, Colorectal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) +1

Start: 2025-05-21End: 2028-05-31Target: 230Updated: 2025-06-03

Phase 3

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

RecruitingNCT06897644

Gruppo Oncologico del Nord-OvestPancreatic Adenocarcinoma Advanced or Metastatic

Start: 2025-03-27End: 2030-01-01Target: 340Updated: 2025-05-25

Related Papers

A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.

2025-11-28